What the studies show
SUSTAIN programme; the original approval basis in type 2 diabetes.
“Mean baseline HbA1c was 8·05% (SD 0·85); at week 30, HbA1c significantly decreased by 1·45% (95% CI -1·65 to -1·26) with 0·5 mg semaglutide (estimated treatment difference vs placebo -1·43%, 95% CI -1·71 to -1·15; p<0·0001), significantly decreased by 1·55% (-1·74 to -1·36) with 1·0 mg semaglutide (estimated treatment difference vs placebo -1·53%, -1·81 to -1·25; p<0·0001), and non-significantly decreased by 0·02% (-0·23 to 0·18) with placebo.”
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in type 2 diabetes (SUSTAIN 1).Lancet Diabetes Endocrinol, 2017First of the SUSTAIN programme.
In context
Semaglutide is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes and, at a higher dose, for weight management. In large randomised trials it produces roughly 15% average weight loss over 68 weeks and reduces major cardiovascular events in people with existing heart disease. Gastrointestinal side effects are common and are the main reason people stop. It is a prescription medicine; products sold outside that channel are unlicensed copies.
Semaglutide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Semaglutide proven to help with blood glucose?
What studies are behind the grade?
Is Semaglutide approved for this?
Other outcomes for Semaglutide
- ABody weight15+ RCTs
- AMajor cardiovascular events1 large RCT
- AGI side effectsadverseAll trials
- BLean mass lossadverseSub-studies
- BBMI in children aged 6–111 phase 3 RCT topline (n=165)
Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →